Trial Profile
A Phase II Study Using ACP-196 (Acalabrutinib) in Patients With Relapsed/Refractory and Treatment-naïve Deletion 17p CLL/SLL: Pharmacodynamic Assessment of BTK Inhibition and Antitumor Response
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Acalabrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Acerta Pharma
- 12 Dec 2023 Results of extended follow-up analyzing clonal evolution during treatment, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 15 Nov 2023 Planned End Date changed from 31 May 2026 to 1 Apr 2026.
- 18 Jul 2023 Planned End Date changed from 31 Dec 2025 to 31 May 2026.